Telemynd, Inc., a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today provide a business update following its spinoff from Emmaus Life Sciences, Inc. (“Emmaus”) (Nasdaq:EMMA), formerly MYnd Analytics, Inc. In connection with the merger between MYnd Analytics, Inc. and Emmaus Life Sciences, Inc., MYnd Analytics contributed its business, assets and liabilities to Telemynd, Inc., which was spun off by means of a pro rata dividend of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019. The new shares are expected to begin trading on a standalone basis, at which time further updates will be provided. In the meantime, additional information is available on the Company’s website and in the Company’s filings with the Securities and Exchange Commission.
-- Emmaus Shares Expected to Begin Trading Tomorrow on Nasdaq Under Ticker Symbol "EMMA" -- TORRANCE Calif. , July 17, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc., a leader in sickle cell ...
Subject to the satisfaction of the other conditions to the closing of the merger, MYnd will change its name to “Emmaus Life Sciences, Inc.” Emmaus stockholders and other equity holders will receive in the merger shares of common stock of MYnd equal to 94.1% of the fully diluted shares with MYnd stockholders retaining 5.9% of the fully diluted shares. In connection with and prior to the closing of the merger, if all closing conditions are satisfied, MYnd will contribute its current business, assets and liabilities to Telymynd, Inc., its wholly owned subsidiary, and spin off Telemynd by means of a pro rata dividend of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019.
MISSION VIEJO, Calif. and TORRANCE, Calif., June 12, 2019 -- MYnd Analytics, Inc. (Nasdaq: MYND), a predictive analytics company aimed at improving the delivery of mental.
Tracklist: 01 – Tall Bearded Iris Speckled 02 – T.V. Sun 03 – Moonstone 04 – Another Plan 05 – Ahh Auspicious 06 – Crazy Wind 07 – MSR 08 – Time In Yer Mind 09 – Mynd 10 – You Can’t Fall Off A Mountain Release Name: Mosses – T.V. Sun (2020) Size: 82.1 […]
The business, which owns 750 salons, has plans to sell.
MYnd Analytics, Inc. (MYND) , a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease treatment, today provided an update on the planned merger and spin-off transaction announced on January 7, 2019. The respective special stockholder meetings will be held today, July 9, 2019, to consider approval of the proposed merger and spin-off transaction. Subject to approval by holders of record of the companies at the respective special stockholder meetings, MYnd will issue a number of shares of common stock to the current Emmaus shareholders, which will result in MYnd shareholders retaining 5.9% of the fully diluted shares of the 'New Emmaus' post-closing and a pro rata distribution of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019. The companies have set a new Spin-Off Record Date of July 15, 2019 in order to comply with certain NASDAQ and DTC requirements.
Sotheby’s is breaking records in its online sales, earning $100 million to date in 2020 and up 370 percent over last year as the pandemic has escalated the organization’s digitization and attracted new audiences around the globe.